KBC Group’s Filana Therapeutics FLNA Stock Holding History

KBC Group’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,944	Closed	-$5K	–	1892
2024 Q4	$5K	Hold	1,944	–	–	﹤0.01%	1831
2024 Q3	$57K	Buy	+1,944	New	+$44.8K	﹤0.01%	1648

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KBC Group's FLNA Position: Q1 2025 in Review

KBC Group sold out of Filana Therapeutics (FLNA) in Q1 2025, closing a stake of 1,944 shares — an estimated $5K sold.

KBC Group first reported a position in FLNA in Q3 2024 and held it in 2 quarters. The position peaked at $57K in Q3 2024. 117 funds tracked by Wall St. Rank hold FLNA as of Q1 2025.

KBC Group reported no remaining Filana Therapeutics position as of Q1 2025 after selling out during the quarter.
KBC Group sold 1,944 Filana Therapeutics shares in Q1 2025, an estimated $5K.
KBC Group first reported a position in Filana Therapeutics in Q3 2024 and held it in 2 quarters.
KBC Group's Filana Therapeutics position peaked at $57K in Q3 2024.
117 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2025.

Based on KBC Group's 13F filing for Q1 2025, filed 25 Apr 2025.